Nucleic acids encoding a tn3 scaffold comprising a cd40l-specific monomer subunit
AssigneeViela Bio, Inc.
InventorsAnthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David SPENCER
Life of this patent
Estimating the term…
Abstract
The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
Claims34
1-121. (canceled)
A method of treating an autoimmune disease in a patient in need thereof comprising administering an effective amount of a composition comprising a Tn3 scaffold, wherein the Tn3 scaffold comprises at least one CD40L-specific monomer subunit, wherein the monomer subunit comprises seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG, wherein the AB loop comprises SEQ ID NO:
- 4, the BC loop comprises a sequence selected from the group consisting of SEQ ID NOS:
- 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, and 168, the CD loop comprises SEQ ID NO:
- 6, the DE loop comprises a sequence selected from the group consisting of SEQ ID NOs:
- 94, 95, 96, 97, 98, and 169, the EF loop comprises SEQ ID NO:
- 8, and the FG loop comprises a sequence selected from the group consisting of SEQ ID NOS:
- 9, 99, 139, and 170.
Dependencies are inferred from the claim text.